72
Participants
Start Date
September 21, 2021
Primary Completion Date
September 26, 2026
Study Completion Date
September 26, 2026
Pembrolizumab (+) Berahyaluronidase alfa
Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.
Pembrolizumab
Participants will receive pembrolizumab 400 mg IV.
Pemetrexed
Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
Carboplatin
Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Paclitaxel
Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Nab-paclitaxel
Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Axitinib
Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
Cisplatin
Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Magyar Honvedseg Egeszsegugyi Kozpont-Onkologiai Osztaly ( Site 0020), Budapest
Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0021), Budapest
Medical Oncology Centre of Rosebank ( Site 0058), Johannesburg
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0053), Sandton
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 0051), Port Elizabeth
Cape Town Oncology Trials ( Site 0050), Cape Town
Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0040), Madrid
Hospital Universitario Virgen de la Victoria-Phase I Trials Unit ( Site 0042), Málaga
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco
FALP-UIDO ( Site 0101), Santiago
Bradfordhill ( Site 0100), Santiago
Kansai Medical University Hospital ( Site 0112), Hirakata
Saitama Prefectural Cancer Center ( Site 0110), Ina-machi
Shizuoka Cancer Center ( Site 0111), Nagaizumi-cho,Sunto-gun
National Hospital Organization Kyushu Cancer Center ( Site 0114), Fukuoka
Osaka International Cancer Institute ( Site 0113), Osaka
Steve Biko Academic Hospital-Medical Oncology ( Site 0057), Pretoria
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0052), Pretoria
Severance Hospital, Yonsei University Health System ( Site 0062), Seoul
Samsung Medical Center ( Site 0063), Seoul
HOSPITAL CLÍNIC DE BARCELONA-Department of Medical Oncology ( Site 0043), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY